Bone and Mineral Metabolism
Bone and mineral metabolism is the area of internal medicine and rheumatology concerned with how the skeleton is built, maintained, and remodeled, and how the body regulates calcium, phosphate, and the hormones that govern them. It links the cellular biology of bone to the metabolic bone diseases — osteoporosis chief among them — that weaken the skeleton and cause fractures.
Definition
Bone and mineral metabolism encompasses the physiologic processes that regulate skeletal mass and mineral homeostasis and the metabolic bone diseases (MeSH: Bone Diseases, Metabolic) that arise when these processes are disturbed.
Scope
This area orients the reader to the structure and turnover of bone, the systemic regulation of calcium and phosphate, the assessment of fracture risk, and the metabolic bone disorders managed in rheumatology and endocrinology. It collects the essentials of bone biology, fracture-risk assessment, osteoporosis, its pharmacologic management, and drug-induced bone disease. It is a reference orientation, not clinical guidance, and it does not give individualized diagnostic or treatment advice.
Sub-topics
Core questions
- How is the balance between bone formation and bone resorption regulated?
- How do calcium, phosphate, vitamin D, and parathyroid hormone maintain mineral homeostasis?
- How is the risk of fragility fracture measured and interpreted?
- What distinguishes osteoporosis from other metabolic bone diseases?
- How do drugs and systemic conditions impair bone strength?
Key concepts
- Bone remodeling cycle
- Osteoblasts, osteoclasts, and osteocytes
- RANK/RANKL/osteoprotegerin signaling
- WNT signaling and sclerostin
- Calcium and phosphate homeostasis
- Parathyroid hormone and vitamin D
- Bone mineral density and fragility fracture
- Metabolic bone disease
Mechanisms
The skeleton is continuously renewed through remodeling, in which osteoclasts resorb old bone and osteoblasts deposit new matrix that subsequently mineralizes. Coupling of these activities is coordinated locally by the RANK/RANKL/osteoprotegerin axis, which controls osteoclast formation, and by WNT signaling and its inhibitor sclerostin, which regulate osteoblast activity. Systemically, parathyroid hormone, vitamin D, and the supply of calcium and phosphate keep mineral concentrations within narrow limits, drawing on the skeleton as a mineral reservoir. When resorption outpaces formation, or when mineralization fails, bone mass and quality decline and fracture risk rises.
Clinical relevance
Metabolic bone diseases are common causes of fracture, disability, and loss of independence, and understanding their shared biology underpins how fracture risk is assessed and how bone-directed therapies act. This area describes the concepts that inform clinical reasoning about skeletal health; it is educational reference material and not a basis for individual diagnosis or treatment.
Epidemiology
Osteoporosis and related fragility fractures are among the most prevalent metabolic bone problems worldwide, with hip and vertebral fractures carrying substantial morbidity, mortality, and cost; the burden rises steeply with age and is projected to grow as populations age (Compston et al., 2019).
Evidence & guidelines
The evidence base spans laboratory studies of bone cell signaling, observational data on fracture epidemiology, and randomized trials and guidelines on assessment and therapy. Dietary reference intakes for calcium and vitamin D from the Institute of Medicine (Ross et al., 2011) are a foundational guidance document for skeletal health across this area.
History
Modern bone and mineral metabolism grew from the mid-twentieth-century characterization of calcium-regulating hormones and the histologic study of bone turnover, and was transformed around the turn of the twenty-first century by the discovery of the RANK/RANKL/osteoprotegerin and WNT/sclerostin signaling systems, which revealed molecular targets later exploited by therapy.
Key figures
- Juliet Compston
- Roland Baron
- Lorenz Hofbauer
- B. Lawrence Riggs
Related topics
Seminal works
- compston-2019
- hofbauer-2000
- baron-2013
Frequently asked questions
- What is a metabolic bone disease?
- It is a disorder in which the systemic regulation of bone turnover or mineralization is disturbed, weakening the skeleton; osteoporosis is the most common example, but the category (MeSH: Bone Diseases, Metabolic) also includes conditions such as osteomalacia and renal bone disease.
- How does this area relate to rheumatology and endocrinology?
- Bone and mineral metabolism sits at the interface of both: rheumatologists frequently assess and follow bone health in inflammatory and glucocorticoid-treated patients, while the hormonal regulation of calcium overlaps heavily with endocrinology.